Wednesday, August 17, 2022 9:48:46 AM
Malcom Gladwell’s latest hypothesis is that the ability to change one’s mind is an attribute. I’ve come to the realization that from time of application, MAA can actually be a faster process than the Commercial manufacturing license process, because of the new and speedier pathways available in the UK. Being that is a possibility, my comment that application for MAA should be submitted no more than 30 days after commercial license application could display my idiocy, not NWBO’s. While I may be only a few weeks off, it would seem that if one files an MAA too soon after commercial license for manufacturing application, the cart might arrive before the horse which is not how the system works. Anyway, to the best of my thinking, for what that’s worth, based upon many factors, I’d say we are currently within a one month window for an MAA acceptance announcement spanning from now to about September 15.
DI’s email response to me yesterday in response to my query whether they would announce any MAA acceptance promptly was responded to quickly with the comment that it is a milestone.
Well, so is submitting it, so I guess they will announce any acceptance promptly, but they might also, I suppose, announce submission, although the two may be so close in time, if validation is rapid, that any announcements might be simultaneous.
Best wishes to patients.
DI’s email response to me yesterday in response to my query whether they would announce any MAA acceptance promptly was responded to quickly with the comment that it is a milestone.
Well, so is submitting it, so I guess they will announce any acceptance promptly, but they might also, I suppose, announce submission, although the two may be so close in time, if validation is rapid, that any announcements might be simultaneous.
Best wishes to patients.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
